Article: A BIG GUN IN TOUGH SPOT

The odds of earning a buck investing in any young biotech company are horse-track long. Any chief executive who can make that proposition work profitably over and over is doing something special.

Mark Skaletsky is my candidate for the most successful serial CEO of Massachusetts biotech start-ups. It's been 23 years since Skaletsky resigned a job at Bristol-Myers to work above a Cambridge restaurant as the third American employee at an obscure new company, Biogen Inc. He left years later, by then the public Biogen's president, to run another new, local venture that was later sold profitably as it prepared to go public. Still later, Skaletsky hit it big with yet another start-up, Geltex ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!